Navigation Links
Peramivir in Medical News

BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza

A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that a double-blind, placebo-controlled, Phase 2 study of intravenous (i.v.) pe...

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

... and potential emergency use of intravenous (i.v.) peramivir in the U.S. "Our efforts at BioCryst remain focused on moving our leading peramivir and forodesine clinical development programs forwa...iligently with government agencies to provide i.v. peramivir as a potential treatment option for an influenza e...

BioCryst to Present at the 11th Annual BIO CEO & Investor Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008

...ear contract to BioCryst to advance development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that the...

BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007

...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...

BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

...n have a new form of anti-viral therapy to effectively manage the bird flu threat. "The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza...
Peramivir in Medical Technology

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...

BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009

BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...

BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza

BIRMINGHAM, Ala., July 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza. The double-blind, placebo-controlled, parallel group Phase II tria...

BioCryst Updates Peramivir Clinical Development Plan

BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir. (Lo...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramiv...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramusc...

Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma

...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...
Peramivir in Biological News

Peramivir protects mice from lethal H5N1 infection

... The antiviral drug peramivir might offer humans significant protection during a...day versus eight days); route of administration of peramivir (intramuscular injections alone versus intramuscul...ice). In all cases, the investigators administered peramivir to mice one hour after nasally administering a let...
Peramivir in Biological Technology

BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza

BIRMINGHAM, Ala., Sept. 19 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary findings from a Phase II study with intramuscular (i.m.) injection of peramivir, the Company's product candidate for the treatment of seasonal and life-threatening i...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and Forodesine HCl programs and a reduction in cos...red in the Phase 3 program of intramuscular (i.m.) peramivir for outpatient influenza. The Company initiated t...

BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

...0, 2007. This decrease is driven by a reduction in peramivir clinical development costs and associated revenue ... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and forodesine HCl program and a reduction in cost...

BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza

...ty of five days of therapy with either 200 mg i.v. peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in ...ficacy endpoints between the three treatment arms. peramivir was generally safe and well-tolerated at these dos...

BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

...ble-Blind, Placebo-Controlled Study of Intravenous peramivir in Acute Influenza Patients" (Poster Session # 302...y and Pharmaceutical Sciences. About Peramivir peramivir is an antiviral agent that inhibits the interactio...d of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are ...

BioCryst to Present at the JMP Healthcare Focus Conference

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

BioCryst to Present at UBS 2008 Global Life Sciences Conference

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...
Other Tags
(Date:3/27/2015)... Trail mix is the perfect, healthy snack for families ... during the game! It’s portable, lightweight and provides a wide ... a new line of specialty trail mixes that satisfy your ... packed with nutritious, 100% all natural ingredients. , These tasty ... protein and fiber to your diet and boost energy. The ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Since September 2014, ... in his comeback tour after having been in retirement for ... eager for the performer to return to touring, and concert ... tickets for Omaha will likely sell out for the two ... BuyCheapTicketsToEvents.com to view the inventory of discounted Garth ...
(Date:3/27/2015)... April 2015 is the 150th anniversary of the end ... bloodiest war and the amazing President that led our country ... the Civil War and Abraham Lincoln. This moving event will ... Jane Pickens Theater in Newport, RI. , Chief Justice ... the master of ceremonies. Dr. Fred Zilian, educator, writer and ...
(Date:3/27/2015)... San Diego, CA (PRWEB) March 27, 2015 ... in February 2015 (case number 1:15-cv-10429, U.S. District Court, ... District Court of the Eastern District of Pennsylvania), the ... of Melinda J. Helbock, A.P.C. are announcing that they ... on behalf of women who were prescribed Zofran ...
(Date:3/26/2015)... Let’s not lose focus of why ... today’s traffic magnets. Three out of 4 consumers choose ... produce department, according to a Packaged Facts survey. Produce ... looking to add more fruits and vegetables to their ... is April 2. As featured in the Chase’s Calendar ...
Breaking Medicine News(10 mins):Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
Other Contents